Adverse HBOC-endothelial dysfunction synergism: A possible contributor to adverse clinical outcomes?

Current Drug Discovery Technologies

Volumn 9, Issue 3, 2012, Pages 194-203

  Biro, George P ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiotensin; Atherosclerosis; Coronary vascular disease; Diabetes; Endothelial dysfunction; Endothelial function; Endothelin; Endothelium; Guanylyl cyclase; Hemoglobin; Hemoglobin based oxygen carrier; Hypertension; Nitric oxide; Nitric oxide synthase; Peroxynitrite; Prostaglandins; Reactive oxygen species; Vascular smooth muscle; Vasoconstriction; Vasodilation

Indexed keywords

ENDOTHELIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOGLOBIN DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; AUTOREGULATION; BIOAVAILABILITY; BLOOD FLOW; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; METABOLIC DISORDER; PRIORITY JOURNAL; VASOCONSTRICTION;

BLOOD SUBSTITUTES; CLINICAL TRIALS AS TOPIC; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HEMOGLOBINS; HUMANS; NITRIC OXIDE; OXYGEN; REACTIVE OXYGEN SPECIES;

EID: 84865437557     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312802650733     Document Type: Article

References (87)

1. Burhop K, Gordon D, Estep T. Review of hemoglobin-induced myocardial lesions. Art Cells Blood Substit Immob Biotechnol 2004; 32(3): 353-74.
2. Ning J, Wong LT, Christoff B, Carmichael FJ, Biro GP. Haemodynamic response following a 10% topload infusion of Hemolink in conscious, anaesthetised and treated spontaneously hypertensive rats. Transfus Med 2000; 10: 13-22.
3. Luschert TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8: 344-8.
4. Silverman TA, Weisskopf RB. Hemoglobin-based oxygen carriers: current status and future directions. Transfusion 2009; 49: 2495-515.
5. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. J Amer Med Assoc 2008; 299: 2304-12.
6. Furchgott RF, Zawadski ZV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
7. Biro GP, Taichman GC, Lada B, Keon WJ, Rosen AL, Sehgal LR. Coronary vascular actions of stroma-free hemoglobin preparations. Artif Org 1988; 12: 40-50.
8. Furchgott RF, Cherry PD, Zawadski JV, Jothianandan D. Endothelial cells as mediators of vasodilation of arteries. J Cardiovasc Pharmacol 1984; 6 (Suppl 2): S336-43.
9. Endeman H, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004; 15: 1983-92.
10. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RO. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4-22.
11. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multi-faceted disorder. Am J Physiol Heart Circ Physiol 2006; 291: H985-H1002.
12. Hong D, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 2005; 1: 55-71.
13. Ignarro LJ, Buga GM, Woods KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor from pulmonary artery and vein is nitric oxide. Proc Nat Acad Sci 1987; 84: 9265-69.
14. Ignarro LJ, Byrns RE, Buga GM, Woods KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61: 866-79.
15. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327(6122): 524-6.
16. Hill BG, Danka BP, Bailey SM, Lancaster JR, Darley-Usma VM. What part of NO don't you understand? Some answers to the cardinal questions in nitric oxide biology. J Biol Chem 2010; 285: 19699-704.
17. Feletou M, Kohler R, Vanhoutte PM. Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and treatment targets. Curr Hypertens Res 2010; 12: 267-75.
18. Schulz E, Jensen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress and endothelial dysfunction in hypertension. Antiox Redox Signal 2008; 10: 1115-26.
19. Donato AJ, Gano LB, Eskurza I, Silver AE, Jablonski K, Seals DR. Vascular endothelial dysfunction with aging: Endothelin-1 and nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009; 297: H425-H32.
20. Dekker RJ, van Thienen JV, Rohlena J, et al. Endothelial KLF2 links arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 2005; 167: 609-18.
21. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 322: 411-5.
22. Granger JP. Endothelin. Am J Physiol Regul Integr Comp Physiol 2003; 285: R298-R301.
23. Hynynen MM, Khalil RA. The vascular endothelial system in hypertension-recent patents and discoveries. Cardiovasc Drug Discov 2006; 1: 95-108.
24. Vanhoutte PM, Tang EHC. Endothelium-dependent contraction: when a good guy turns bad. J Physiol 2008; 586: 5295-304.
25. Kirkby NS, Hadoke PWF, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Brit J Pharmacol 2008; 153: 105-19.
26. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-9.
27. Stauffer BL, Westby CM, De Souza CA. Endothelin-1, aging and hypertension. Curr Opin Cardiol 2008; 23: 350-55.
28. Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 2001; 38 [Suppl2]: S3-S6.
29. Atlas AS. The renin-angiotensin-aldosterone system: pathophysiological role and pharmacologic inhibition. J Manage Care Pharm 2007; 13: 9-20.
30. Siragy HM, Carey RM. Role of intrarenal renin-angiotensin aldosterone system in chronic kidney disease. Am J Nephrol 2010; 36: 541-50.
31. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Exper Physiol 2010; 459: 923-39.
32. Alayash A. Oxygen therapeutics: can we tame hemoglobin? Nature Rev Drug Discover 2004; 3: 152-9.
33. Belcher JD, Beckman JD, Balla J, Vercelotti G. Heme degradation and vascular injury. Antioxidant Redox Signal 2010; 12: 233-48.
34. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. The aging endothelium, cardiovascular risk and disease in man. Exper Physiol 2008; 94: 317-21.
35. Taddei S, Virdis A, Ghianoni L, Sudano I, Salvetti A. Defective l-arginine nitric oxide in offspring of essential hypertensive patients. Circulation 1996; 94: 1298-303.
36. Aird WC. Endothelium as an organ system. Crit Care Med 2004; 32: S271-S79.
37. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxidant Redox Signal 2008; 10: 1713-65.
38. Van der Loo B, Schildknecht S, Zee R, Bachschmid M. Signalling processes in endothelial aging in relation to chronic oxidative stress and their potential therapeutic implications in humans. Exper Physiol 2009; 94: 305-10.
39. Erusalimsky JD, Skene C. Mechanisms of endothelial senescence. Exper Physiol 2008; 94: 299-304.
40. Aird WC. Mechanisms of endothelial heterogeneity in health and disease. Circ Res. 2006; 94: 299-304.
41. Hai CM. Systems biology of HBOC-induced vasoconstriction. Clin Drug Develop Technol 2012; 9(3): 00-00.
42. Duncker DJ, Merkus D. Acute adaptations of the coronary circulation to exercise. Cell Biochem Biophys 2005; 43: 17-35.
43. Toda N, Imamura T, Okamura T. Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol Therap 2010; 127: 189-209.
44. Minneci PC, Deans KJ, Zhi H, et al. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized hemoglobin. J clin Invest 2005; 115: 3409-17.
45. Hebbel RP. Reconstructing sickle cell disease: A data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Amer J Hematol 2011; 86: 123-54.
46. Bunn HF, Nathan DG, Dover GJ, et al. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116: 687-92.
47. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radic Biol Med 2008; 44: 1606-28.
48. Alayash A, D'Agnillo F, Buehler PW. First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives. Expert Opin Therap 2007; 7: 665-75.
49. Buehler PW, D'Agnillo F. Toxicological consequences of extracellular hemoglobin: biochemical and physiological perspectives. Antioxidant Redox Signal 2010; 12: 275-91.
50. Alayash A, Brockner I, Ryan BA, Cashon RE. Peroxynitrite-mediated heme oxidation and protein modification of native and chemically modified hemoglobins Arch Biochem. Biophys 1998; 349: 65-73.
51. Widmer C, Pereira CP, Gehrig P, et al. Hemoglobin can attenuate hydrogen peroxide-induced oxidative stress by acting as an antioxidant peroxidase. Antixidant Redox Signal 2010; 12: 185-98.
52. Sharma AC, Singh G, Gulati A, Rebello S. Role of NO mechanism in cardiovascular effects of diaspirin cross-linked hemoglobin in anesthetized rats. Amer J Physiol Heart Circ Physiol 1995; 269: H1379-H88.
53. Gulati A, Sen AP, Sharma AC, Singh G. Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat Amer J Physiol Heart Circ Physiol. 1997; 273: H827-H36.
54. Pape A, Kleen M, Kemming G, Meier J, Habler O. Fluid resuscitation from severe hemorrhagic shock using diaspirin cross-linked hemoglobin fails to improve pancreatic and renal perfusion. Acta Anaesth Scand 2004; 48: 1328-37.
55. Dietz NM, Crestin MM, Beltran-del-Rio AG, Joyner MJ. The effects of cross-linked hemoglobin on regional vascular conductance in dogs. Anest Analg 1997; 85: 265-73.
56. Krieter H, Hagen G, Waschke KF, et al. Isovolemic hemodilution with a bovine hemoglobin-based oxygen carrier: Effects on hemodynamics and oxygen transport in comparison with a nonoxygen carrying volume substitute. J cardiothorac vasc Anesthesia 1997; 11: 3-9.
57. Torres Filho IP, Spiess B, Barbee RW, Ward KR, Oldenhof J, Pitman RN. Systemic responses to hemodilution after transfusion with stored blood and with a hemoglobin-based oxygen carrier. Anesth Analg 2005; 100: 912-20.
58. Gulati A, Rebello S. Role of adrenergic mechanisms in the pressor effects of diaspirin cross-linked hemoglobin. J lab clin Med 1994; 124: 125-33.
59. Ledvina MA, Hart J, Bina S, Jing M, Muldoon S. Endothelin plays a role in contractions of isolated pig pulmonary vessels induced by diaspirin cross-linked hemoglobin. J Lab clin Med 1999; 133: 478-87.
60. Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin cross-linked and stroma reduced hemoglobin. Crit Care Med 1996; 24: 137-47.
61. Rioux F, Harvey N, Moisan S, et al. Nonpeptide endothelin antagonists attenuate the pressor effect of diaspirin cross-linked hemoglobin in rats. Can J Physiol Pharmacol 1999; 77: 188-94.
62. Fischer SR, Traber DL. L-arginine and endothelin receptor antagonist Bosentan counteract hemodynamic effects of modified hemoglobin. Shock 1999; 11: 283-90.
63. Simoni J, Simoni G, Moeller JF, Tsikouris JP, Wesson DE. Evidence of angiotensin converting enzyme (ACE)-like activity of acellular hemoglobin. Artif Cells Blood Substit Immob Biotechnol 2007; 35: 191-210.
64. Conhaim RL, Cooler SD, Mc Grath AM, De Angeles DA, Myers GA, Harms BA. Filtration of diaspirin cross-linked hemoglobin into lung and soft tissue lymph. Amer J Respir Crit Care Med 1998; 158: 1204-12.
65. Faivre-Fiona B, Caron A, Fassot C, et al. Presence of hemoglobin inside aortic endothelial cells after cell-free hemoglobin administration in guinea pigs. Amer J Physiol Heart Circ Physiol 1999; 276: H766-H70.
66. Nagabugu E, Ramasamy S, Rifkind JM, Jia Y, Alayash A. Site-specific cross-linking of human and bovine hemoglobins differentially alters oxygen binding and redox side reactions producing rhombic heme and heme degradation. Biochemistry 2002; 41: 7407-15.
67. Haney CR, Buehler PW, Gulati A. Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers. Adv Drug Deliv Rev 2000; 40: 153-69.
68. Buehler PW, Alayash AI. All hemoglobin-based oxygen carriers are not created equally. Biochim Biophys Acta 2008; 1784: 1378-81.
69. Loscalzo J. Nitric oxide binding and the adverse effects of cell-free hemoglobins: What makes us different from earthworms? J Lab clin Med 1997; 129: 580-3.
70. Kim-Shapiro DB, Schecter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite and hemoglobin physiology and therapeutics. Atheroscler Thromb Vasc Biol 2006; 26: 697-705.
71. Levy AP, Asleh R, Blum S, et al. Haptoglobin: Basic and clinical aspects. Antioxidant Redox Signal 2010; 12: 293-304.
72. Scher DJ, Alayash A. Clearance and control mechanisms of hemoglobin from cradle to grave. Antioxidant Redox Signal 2010; 12: 181-4.
73. Boretti FS, Buehler PW, DÁgnillo F, et al. Sequestration of extracellular hemoglobin within the haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J clin Invest 2009; 119: 2271-80.
74. Kato GJ. Haptoglobin halts hemoglobin's havoc. J clin Invest 2009; 119: 2140-2.
75. Yu B, Raher MJ, Volpato GP, Bloch KD, Ichinose F, Zapol WM. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 2008; 117: 1982-90.
76. Chang TMS. Nanobiotechnology for hemoglobin-based blood substitutes. Crit Care Med 2009; 25: 373-82.
77. Yu B, Shaid M, Egorina EM, et al. Endothelial dysfunction enhances vasoconstriction due to scavenging nitric oxide by a hemoglobin based oxygen carrier. Anesthesiology 2010; 112: 586-94.
78. Baldwin AL. Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery. Amer J Physiol Heart Circ Physiol 1999; 277: H650-H9.
79. Dull RO, De Witt BJ, Dinavahi R, Baldwin AL, et al. Quantitative assessment of hemoglobin-induced endothelial barrier dysfunction. J appl Physiol 2004; 9: 1930-37.
80. Boueiz A, Hassoun PM. Regulation of endothelial barrier function by reactive oxygen and nitrogen species. Microvasc Res 2009; 77: 26-35.
81. Intaglietta M, Cabrales P, Tsai A. Microvascular perspectives of oxygen carrying and non-oxygen carrying blood substitutes. Annu Rev Biomed Engineering 2006; 89: 289-321.
82. Meisner FG, Kemming GI, Habler OP, et al. Diaspirin cross-linked hemoglobin enables extreme hemodilution beyond the critical hematocrit. Crit Care Med 2001; 29: 829-38.
83. Caswell JE, Strange MB, Rimmer DM, Gibson MF, Cole P, Lefer DJ. A novel hemoglobin-based blood substitute protects against myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2005; 288: H1796-H801.
84. Canty JM, Smith TP. Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide. Int J Cardiol 1995; 50: 207-15.
85. Kinlay S, Behrendt D, Wainstein M, et al. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104: 1114-8.
86. Bohm F, Jensen J, Svane B, Settergren M, Pernow J. Intracoronary endothelin receptor blockade improved endothelial function in patients with coronary artery disease. Can Physiol Pharmacol 2008; 86: 745-51.
87. Estep T, Bucci E, Greenburg G, et al. Basic science focus on blood substitutes: A summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008; 48: 776-82.